Teladoc Health enhances obesity management with GLP-1 support

Teladoc Health, a global leader in virtual care, has expanded its capabilities to address the increasing demand for anti-obesity medication, focusing on glucagon-like peptide 1 (GLP-1) agonists, and supporting safe, sustainable weight loss and cardiometabolic health. The Comprehensive Weight Management solution, tailored for health plans and employers, includes personalised, evidence-based approaches provided by experienced clinicians in obesity management, health coaching, medical nutrition therapy, and mental health support. 

The program aims to tackle obesity-related medical expenses by optimising the use of anti-obesity medications, integrating lifestyle modifications, and ensuring a unified member experience across various health management programs. With over 40% of American adults estimated to have obesity, Teladoc Health recognises obesity as a complex, lifelong condition requiring personalised and longitudinal care.

The expanded features also include care coordination with non-Teladoc Health physicians, lab testing, and the optimisation of GLP-1s and other anti-obesity medications. The program adopts a multidisciplinary care model designed by clinicians experienced in obesity medicine and emphasises a holistic weight loss strategy addressing key pillars of cardiometabolic health: nutrition, physical activity, sleep, and stress management. 

Teladoc Health aims to provide comprehensive and integrated clinical care that considers individual well-being, mental health, and social drivers of health in a personalised manner. The company emphasises sustained results by addressing comorbidities and cultural preferences while minimising side effects and associated medication costs. The initiative acknowledges the growing obesity crisis and seeks to offer effective, long-term solutions for individuals with obesity.